Spain announces big drug-price cuts, aiming for $1.6 billion savings

17 May 2010

In a move that has been described as a 'mortal blow' to Spain's pharmaceutical in some Spanish press reports, the nation's government has announced that it is cutting the prices of patented prescription drugs by as much as 23% in the hope of reducing what the public health system spends on medicines. The savings should amount to roughly 1.3 billion euros ($1.6 billion).

The price paid by the government for generics has also been reduced by 25%, and the European Generic Medicines Association (EGA) has recently written to the Spanish Health and Social Policy Minister saying that price cuts must be followed by an increase in patients' access to generic medicines (The Pharma Letter May 10).

Follows Greek moves

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics